Ten billion-level heavyweight varieties piled up the stone drug "Imatimi", Jingxin "Pivastatin calcium":

Text . . . As of July 24, CDE has a total of 2233 consistency evaluation acceptance numbers (530 varieties of 587 enterprises, according to supplementary applications, the same below), of which 615 have been accepted; On the 24th of the month, the same below) passed four more varieties, including the heavy varieties of the new drug industry in Beijing, Zhejiang Province, as well as the 10 billion-dollar market of sulphate clopidore tablets, 13 varieties approved, the evaluation is immediately, and 13 varieties were accepted ... Reviewed the details of 4 varieties have been reviewed, stone drug European "Imatini" this week listed 4 varieties through consistency evaluation, of which 2 varieties are the first, for Zhejiang Jing new drug industry pivastatin calcium dispersion tablets and Shanghai Qingping PharmaceuticalSs sodium valproate tablets;
this week's consistency evaluation of the details of pivastatin calcium dispersed tablets of statins is the third generation of statins, is currently used in international clinical treatment of hypercholesterolemia, familial hypercholesterolemia, one of the better effects of statins.
According to IQVIA data, domestic sales of pivastatin tablets exceeded 1 billion yuan in 2019.
according to the data of the drug, pivastatin calcium dispersion tablets for the Beijing new pharmaceutical industry exclusive dosage type varieties, and is now successful through consistency evaluation, into the collection of mining, to help it to do strong cardiovascular field, improve performance to bring positive impact.
at present, Beijing New Pharmaceuticals has 8 products 11 specifications through consistency evaluation.
Beijing New Pharmaceutical Industry consistency evaluation of the details of the table picture source: Beijing New Pharmaceutical Officer micro sulphate clopilando gramopyriela tablets sulphate pyridoxine tablets, mainly used for the treatment of recent myocardial infarction and acute coronary syndrome, has been included in the National Health Insurance Directory (2019 edition).
According to corporate announcements, China's public medical institutions end market in 2018 clopidogrel annual sales of about 12.24 billion yuan, 2019 about 11.57 billion yuan, according to pharmaceutical hospital sales data show that the sample hospital sales of more than 60% of the market share is the original research enterprise Sanofi, followed by Sanofi and Lepu Pharmaceuticals.
in addition, according to the drug-intelligence consistency evaluation progress database, so far, a total of five enterprises through or as if through the consistency evaluation, Dr. Reddy Laboratory in India for the fifth evaluation enterprises.
of which Nanjing Zhengda Tianqing and stone medicine European-Italian are regarded as the same review, stone medicine Europa "sulphate chlorpyrifos tablets" belong to the "common line at home and abroad, approved in the United States listed" last year in the domestic approved listing of varieties, in accordance with the relevant provisions as through the consistency evaluation.
picture source: drug intelligence data worth mentioning is the sulphate chlorpyrifos tablets for the "4 plus 7" band procurement products, Lepu Pharmaceuticals is the first through consistency evaluation of the enterprise, but did not seize the opportunity in the 4 plus 7, so that the second evaluation of the Xinlitai winning bid, now the sulphate chlorpyrifos tablets have been evaluated by five enterprises, the third round of collection callout, 100 billion chlorogray preparations will become more intense market competition.
amatinib is an oral tyrosine kinase inhibitor drug, is a first-line drug for the treatment of chronic myeloid leukemia (CML), can make CML patients 10 years survival rate of 85% to 90%, greatly extended the life cycle of patients, known as "slow-grain leukemia life-saving drugs."
, developed by Novartis, was first approved by the U.S. Food and Drug Administration (FDA) on May 10, 2001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
was approved to enter China in April 2002. according to public data
, global sales of Imartini tablets of methfothane were more than $4 billion in 2016 and $1,263 million in 2019.
Sales of The Hospital of Grewe in 2019 amounted to RMB1,226 million, according to sales data from pharmaceutical hospitals.
according to pharmaceutical data, the domestic Imatini has 3, for Haussen, Zhengda Qing and Stone Pharmaceutical Group, which is the capsule, Howson and stone medicine Oyi for the tablet, now 3 enterprises are through the consistency evaluation, and Howson and Zhengda Tianqing of the variety in the Alliance region with a volume of procurement with 10.38 yuan / tablets and 9.77 yuan .
review and approval of 13 varieties in the immediate, Catopuri tablets through the enterprise will break 10 this week in addition to 2 varieties successfully broke through the consistency evaluation, there are 13 varieties will soon be evaluated, of which 2 injections approved, for Boda Pharmaceutical's Ida Dara fend injection and Kaifeng Pharmaceutical's thiocitacid injection.
this week's consistency evaluation review and approval details, it is worth mentioning that the Captopri tablet is currently through the consistency evaluation of enterprises within top10 drugs, there are currently 10 enterprises have been evaluated, such as if Kaifeng Pharmaceuticals and Huazhong Pharmaceuticals successfully passed, will be the 11th through the variety of enterprises.
picture source: pharmaceutical data declaration acceptance 13 varieties were contracted, 10 billion contrast agent another species of the first declaration this week CDE new consistency evaluation acceptance number 15 (13 varieties), of which 2 varieties for the first time declared accepted varieties, for Beijing North Land Pharmaceuticals of the oxamine glucose injection and Dissa Pharmaceuticals hydrochloric acid amphetamine sequinrelease tablets.
this week's consistency evaluation declaration acceptance details table worth mentioning is that the oxytocin glucosamine injection is an magnetic resonance contrast agent.
data show that in 2019, domestic contrast agent sales of about 15.2 billion yuan, up 10.4% YoY, of which iodized sea alcohol injection, iodized salsal injection as the representative of iodized salt X-ray contrast agent accounted for 83.71 percent of the market share, with oxycodone injection liquid, xylomine injection as the representative of magnetic resonance contrast agent accounted for 12.87 percent.
According to the domestic database of pharmaceutical wisdom, China's existing domestic market approval of oxamine injection, mainly related to Beijing North Land, Guangzhou Kangchen, as well as Shanghai Xudonganpu 3 production manufacturers; Injection sample pharmaceutical sales reached 230 million yuan, the original research Bayer Pharmaceuticals accounted for 40.97 percent, followed by Beijing Beilu Pharmaceuticals accounted for 27.4 percent, is now Beijing Beilu Pharmaceuticals this variety declaration consistency evaluation, smooth evaluation, will further enhance competitiveness, squeeze the original research market share.
image source: drug intelligence data source: drug intelligence data, enterprise announcements and other network public data sources of information: drug intelligence network, enterprise announcements and other network public information.